Video Series

Panelists discuss the main cost drivers of lupus nephritis treatment, comparing direct medical costs to those of other chronic conditions and examining indirect costs such as lost productivity and disability.

Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and incidence of lupus nephritis in various populations.

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

Experts in cardiometabolic risk management examine the factors contributing to low adherence to guidelines for cardiometabolic conditions, with a specific focus on type 2 diabetes.

Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.

Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

A panel of medical experts examines the challenges in managing co-morbid cardiometabolic conditions, emphasizing the most prevalent complications associated with this disease state.

Experts in the field of cardiometabolic risk management analyze the link between obesity and cardiometabolic conditions, outlining challenges and proposing potential solutions.

Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.

Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.

Experts in cardiometabolic risk management explore strategies for the prevention and screening of cardiometabolic conditions.

A panel of experts examines the impact of cardiometabolic diseases in the United States, focusing on their burden, prevalence, and relationship to obesity.

Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.

Jonathan Silverberg, MD, PhD, MPH, evaluates persistent unmet needs in the field and highlights promising new treatments currently under development.

A key opinion leader explores new and promising treatment approaches for managing advanced stages of Friedreich ataxia.

A key opinion leader explores therapeutic approaches targeting inflammation to alleviate symptoms in COPD and asthma patients.

An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.

A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.

A key opinion leader examines how the introduction of biologic therapies revolutionized atopic dermatitis treatment, addressing strategies to manage patients' concerns about needles and injections.

A dermatologist outlines the limitations and obstacles encountered with current therapeutic options for treating dermatologic conditions.

A key opinion leader outlines common adverse events associated with omaveloxolone treatment in Friedreich's ataxia patients and describes strategies used to manage or minimize these adverse effects.

The panelists provide their closing thoughts, highlighting key considerations around biosimilar.

A key opinion leader in dermatology explains how the presence of type 2 inflammation informs their treatment decisions for atopic dermatitis and prurigo nodularis, while also detailing additional patient-specific factors such as age, comorbidities, and disease severity that influence their therapeutic approach.

A dermatologist explores the underlying type 2 inflammatory pathway linking atopic dermatitis and prurigo nodularis, highlighting specific biomarkers that aid in identifying patients with type 2 inflammation-driven dermatologic conditions.

An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.

The expert panel discuss the importance of legislative support to continue innovations in the biosimilar space.